{"nctId":"NCT00014222","briefTitle":"Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer","startDateStruct":{"date":"2000-12-04","type":"ACTUAL"},"conditions":["Breast Cancer"],"count":2104,"armGroups":[{"label":"Arm 1: CEF","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: cyclophosphamide","Drug: epirubicin hydrochloride","Drug: fluorouracil"]},{"label":"Arm 2: EC/T","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: epoetin alfa","Biological: filgrastim","Drug: cyclophosphamide","Drug: doxorubicin hydrochloride","Drug: paclitaxel"]},{"label":"Arm 3: AC/T","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: cyclophosphamide","Drug: doxorubicin hydrochloride","Drug: paclitaxel"]}],"interventions":[{"name":"epoetin alfa","otherNames":[]},{"name":"filgrastim","otherNames":[]},{"name":"cyclophosphamide","otherNames":[]},{"name":"doxorubicin hydrochloride","otherNames":[]},{"name":"epirubicin hydrochloride","otherNames":[]},{"name":"fluorouracil","otherNames":[]},{"name":"paclitaxel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast that is potentially curable\n\n  * T0-4 (dermal involvement on pathology assessment only), N0-2, M0\n  * No clinical T4 disease\n* Previously treated with one of the following:\n\n  * Total mastectomy and level II axillary node dissection\n  * Partial mastectomy and level II axillary node dissection with planned breast radiotherapy after completion of adjuvant chemotherapy regimen\\*\n  * Patients with a positive sentinel node biopsy must undergo level II axillary node dissection or sufficient nodal sampling\n  * If microscopic residual in situ or invasive disease is present at total or partial mastectomy margins, planned radiotherapy must also include a boost to the tumor bed\n* No residual tumor in the axilla after dissection\n* Axillary node positive\n\n  * Negative nodes allowed if the tumor is ≥ 1 cm and 1 or more of the following criteria defining high-risk node-negative disease are met:\n\n    * Histological grade III or,\n    * Estrogen receptor negative or,\n    * Lymphatic/vascular invasion\n* Hormone receptor status:\n\n  * Estrogen receptor status known\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 60 and under\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* Pre- or postmenopausal\n\nPerformance status:\n\n* ECOG 0-2\n\nLife expectancy:\n\n* At least 5 years\n\nHematopoietic:\n\n* WBC ≥ 3,000/mm\\^3\n* Platelet count ≥ 100,000/mm\\^3\n\nHepatic:\n\n* Bilirubin ≤ 1.5 times upper limit of normal (ULN)\n\nRenal:\n\n* Creatinine ≤ 1.5 times ULN\n\nCardiovascular:\n\n* LVEF ≥ limit of normal by MUGA or echocardiogram\n* No arrhythmia requiring ongoing treatment\n* No congestive heart failure\n* No documented coronary artery disease\n\nOther:\n\n* No other malignancy except:\n\n  * Adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n  * Ductal or lobular carcinoma in situ that has been curatively treated by surgery alone\n  * Other prior malignancies (except breast cancer) curatively treated more than 5 years prior to study entry\n* No serious underlying medical illness or psychiatric or addictive disorder that would preclude study compliance\n* No known hypersensitivity to E. coli-derived products, mammalian-cell derived products, or any study agents\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective non-hormonal contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* No prior immunotherapy for breast cancer\n* No concurrent pegfilgrastim or darbepoetin alfa (Arm II)\n\n  * Allowed on arms 1 and 3 if medically necessary\n\nChemotherapy:\n\n* No prior chemotherapy for breast cancer\n\nEndocrine therapy:\n\n* No prior hormonal therapy for breast cancer\n* No concurrent hormone replacement therapy\n* No concurrent selective estrogen-receptor modulators (e.g., raloxifene for the treatment or prevention of osteoporosis)\n* No concurrent oral contraceptives (i.e., birth control pills)\n* No other concurrent aromatase inhibitors\n\nRadiotherapy:\n\n* See Disease Characteristics\n* No prior radiotherapy for breast cancer\n\nSurgery:\n\n* See Disease Characteristics\n* No more than 12 weeks since prior total or partial mastectomy (including re-excision of margins)\n\nOther:\n\n* At least 30 days since prior investigational drugs\n* No other concurrent investigational drugs\n* Concurrent bisphosphonates for the treatment or prevention of osteoporosis allowed","healthyVolunteers":false,"sex":"FEMALE","maximumAge":"60 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease Free Survival","description":"Disease free survival was defined as the time from randomization to the time of recurrence of the primary disease. Local or nodal recurrence and metastatic disease were considered a recurrence of the primary tumour. Patients who had contralateral breast cancer or a second primary malignancy, or died from some cause other than disease were censored as relapse-free at the time of death. Patients who had not relapsed were censored at longest follow-up or at non-breast cancer death. As required, adjudication was used to assess reports of recurrence.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null},{"groupId":"OG001","value":"135","spread":null},{"groupId":"OG002","value":"191","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"560","spread":null},{"groupId":"OG001","value":"566","spread":null},{"groupId":"OG002","value":"511","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival was defined as the time from randomization to the time of death from any cause, with censoring at longest follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"107","spread":null},{"groupId":"OG002","value":"146","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"578","spread":null},{"groupId":"OG001","value":"594","spread":null},{"groupId":"OG002","value":"556","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":83,"n":680},"commonTop":["Fatigue","Alopecia","Nausea","Stomatitis","Hot flashes/ flushes"]}}}